Evidence map›Paper›PMID 39137777›Full record

ArticleCell2024

Macrophage-mediated myelin recycling fuels brain cancer malignancy.

Daan J Kloosterman, Johanna Erbani, Menno Boon, Martina Farber, Shanna M Handgraaf, Masami Ando-Kuri, Elena Sánchez-López, Bauke Fontein, Marjolijn Mertz, Marja Nieuwland and 14 more

Abstract read
In one paragraph

Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Daan J KloostermanDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Johanna ErbaniDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Menno BoonDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Martina FarberDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Shanna M HandgraafDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Masami Ando-KuriDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Elena Sánchez-LópezCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Bauke FonteinDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Marjolijn MertzBioimaging Facility, Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Marja NieuwlandGenomics Core Facility, Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Ning Qing LiuDepartment of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
Gabriel Forn-CuniInstitute of Biology Leiden, Leiden University, Leiden, the Netherlands.
Nicole N van der WelElectron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
Anita E GrootemaatElectron Microscopy Centre Amsterdam, Medical Biology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
Luuk ReinaldaThe Institute of Chemical Immunology, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.
Sander I van KasterenThe Institute of Chemical Immunology, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.
Elzo de WitDivision of Gene Regulation, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Brian RuffellDepartment of Immunology, Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ewa Snaar-JagalskaInstitute of Biology Leiden, Leiden University, Leiden, the Netherlands.
Kevin PetreccaMontreal Neurological Institute-Hospital, McGill University Health Centre and Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, QC, Canada.
Dieta BrandsmaDepartment of Neuro-Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066CX Amsterdam, the Netherlands.
Alexander KrosLeiden Institute of Chemistry, Leiden University, Leiden, the Netherlands.
Martin GieraCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.
Leila AkkariDivision of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands. Electronic address: l.akkari@nki.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors growing in metabolically challenged environments, such as glioblastoma in the brain, are particularly reliant on crosstalk with their tumor microenvironment (TME) to satisfy their high energetic needs. To study the intricacies of this metabolic interplay, we interrogated the heterogeneity of the glioblastoma TME using single-cell and multi-omics analyses and identified metabolically rewired tumor-associated macrophage (TAM) subpopulations with pro-tumorigenic properties. These TAM subsets, termed lipid-laden macrophages (LLMs) to reflect their cholesterol accumulation, are epigenetically rewired, display immunosuppressive features, and are enriched in the aggressive mesenchymal glioblastoma subtype. Engulfment of cholesterol-rich myelin debris endows subsets of TAMs to acquire an LLM phenotype. Subsequently, LLMs directly transfer myelin-derived lipids to cancer cells in an LXR/Abca1-dependent manner, thereby fueling the heightened metabolic demands of mesenchymal glioblastoma. Our work provides an in-depth understanding of the immune-metabolic interplay during glioblastoma progression, thereby laying a framework to unveil targetable metabolic vulnerabilities in glioblastoma.

Indexed as

Brain NeoplasmsGlioblastomaMyelin SheathTumor MicroenvironmentAnimalsATP Binding Cassette Transporter 1Cell Line, TumorCholesterolFemaleHumansLiver X ReceptorsMacrophagesMaleMiceTumor-Associated MacrophagesABCA1 protein, humanATP Binding Cassette Transporter 1CholesterolLiver X Receptorscancer immunitycholesterolglioblastomalipid metabolismmacrophagesmyelin recyclingtumor microenvironment

Identifiers

PMID39137777
PMCPMC11429458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.